Clinical practice must address AI biases by using training, validation, and testing datasets that reflect the target population and avoid underrepresented groups or labeling inaccuracies that could impair performance.

AI enables scalable services such as post-discharge remote monitoring, risk-based prevention programs, virtual specialist support for smaller hospitals, and diagnostics closer to communities while sustaining ongoing patient relationships.

Economic benefits include substantial savings in revenue-cycle operations, with estimates of a 30%–60% reduction in cost-to-collect by early 2026, freeing resources for clinical teams and equipment.

AI-enabled SaMDs are evolving from detection to triage, diagnosis, and treatment guidance, with multimodal data integration across wearables, in vitro diagnostics, and radiology, notably advancing cancer care.

AI-enabled software as medical devices are rapidly expanding in the U.S. and globally, with more than 1,500 AI-enabled SaMDs authorized by early 2026 and a strong rise since 2022, led by radiology and supplemented by cardiology and neurology.

In the United States, FDA authorizations surpassed 1,000 AI-enabled medical devices by early 2025 across radiology, cardiology, and other diagnostics, while the UK NHS moves to adopt AI-enabled ambient scribing to streamline doctor-patient time.

Healthcare AI should aim to reduce delays, improve decision-making, and extend appropriate care to more patients, with long-term value measured by lives touched and health and happiness gains rather than deployment counts.

Judicious use is essential as performance varies by state and population; robust validation, representative data, human oversight, and real-world evaluation methods are needed, with the FDA calling for better real-world evaluation in 2025.

AI is becoming part of point-of-care practice, extending medical knowledge to patients and integrating into consultations, diagnostics, and hospital operations.

This article is part of a sponsored whitepaper series for AI-enabled SaMD developers.

Global regulatory landscapes are tightening and diverging across markets (EU, UK, Canada, Japan, China, Singapore, Australia), with actions focusing on intended use, datasets, architecture, performance criteria, quality systems, cybersecurity, and real-world monitoring.

India has built extensive digital health foundations, with over 100 crore linked health records and Ayushman Bharat Health Accounts; AI can further optimize scheduling, documentation, claims, inventory, and discharge management.